|1|A systematic review and meta-analysis of the evidence base for add-on treatment for patients with major depressive disorder who have not responded to antidepressant treatment: A European perspective. (24108407)
Turner P.... Young A.H.
|2|Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? (24165478)
|3|Health-related quality of life in recurrent major depressive disorder--a 10-year follow-up study. (23245634)
A8rdal G.... Hammar A.8.
|4|Neurovascular unit dysfunction with blood-brain barrier hyperpermeability contributes to major depressive disorder: a review of clinical and experimental evidence. (24289502)
Najjar S.... Zagzag D.
|5|Trigeminal nerve stimulation in major depressive disorder: acute outcomes in an open pilot study. (23773978)
Cook I.A.... Leuchter A.F.
|6|Stigmatizing attitudes differ across mental health disorders: a comparison of stigma across eating disorders, obesity, and major depressive disorder. (23538972)
Ebneter D.S.... Latner J.D.
|7|Distinguishing bipolar disorder from major depressive disorder: does an increased risk of substance use account for other differences? (23231373)
|8|Aripiprazole augmentation for major depressive disorder: dosing patterns in a naturalistic treatment setting. (24108149)
Pae C.U.... Masand P.S.
|9|Epidemiological and clinical characterization following a first psychotic episode in major depressive disorder: comparisons with schizophrenia and bipolar I disorder in the Cavan-Monaghan First Episode Psychosis Study (CAMFEPS). (23716714)
Owoeye O.... Waddington J.L.
|10|Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary. (24432034)
Ball S.G.... Perahia D.G.
|11|Functional connectivity between the amygdala and prefrontal cortex in medication-naive individuals with major depressive disorder. (23953680)
Kong L.... Wang F.
|12|Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. (24229754)
Clayton A.H.... Ninan P.T.
|13|How natural is it for nature to help with major depressive disorder? (23574163)
Witkin J.M.... Li X.
|14|Prevalence of current, 12-month and lifetime major depressive disorder among patients with systemic sclerosis. (23256181)
Jewett L.R.... Thombs B.D.
|15|Study of effects of selective serotonin reuptake inhibitors on stages of sexual function in Iranian patients with major depressive disorder. (24294483)
Safa M.... Ghasem Boroujerdi F.
|16|Remission and functioning in major depressive disorder. (24096391)
Romera I.... Gilaberte I.
|17|EEG-based upper-alpha neurofeedback for cognitive enhancement in major depressive disorder: A preliminary, uncontrolled study. (24111179)
Escolano C.... Minguez J.
|18|Plasma Levels of IL-23 and IL-17 before and after Antidepressant Treatment in Patients with Major Depressive Disorder. (24302954)
Kim J.W.... Lee H.S.
|19|Usefulness of visual evaluation of the anterior thalamic radiation by diffusion tensor tractography for differentiating between Alzheimer's disease and elderly major depressive disorder patients. (23589698)
Niida A.... Uechi A.
|20|Cognitive symptoms in patients with major depressive disorder and their implications for clinical practice. (24345473)
|21|Monoamine oxidases in major depressive disorder and alcoholism. (22890201)
Duncan J.... Ou X.M.
|22|Increases in amplitude of low-frequency fluctuations in left fronto-parietal area after duloxetine therapy in first-episode, drug-naA^ve, major depressive disorder with panic disorder patients. (23037667)
|23|Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. (22880079)
Yoshida T.... Hashimoto K.
|24|Functional impairment related to painful physical symptoms in patients with generalized anxiety disorder with or without comorbid major depressive disorder: post hoc analysis of a cross-sectional study. (21510887)
Romera I.... Gilaberte I.
|25|Poor replication of candidate genes for major depressive disorder using genome-wide association data. (20351714)
Bosker F.J.... Nolen W.A.
|26|Duloxetine's modest short-term influences in subcortical structures of first episode drug-naA^ve patients with major depressive disorder and panic disorder. (21820879)
Lai C.H.... Wu Y.T.
|27|Altered expression of CD4(+)CD25(+) regulatory T cells and its 5-HT(1a) receptor in patients with major depression disorder. (19900711)
Li Y.... Yang H.
|28|Alexithymia and temperament and character model of personality in patients with major depressive disorder. (19932828)
Celikel F.C.... Cloninger C.R.
|29|The role of the inflammatory markers ferritin, transferrin and fibrinogen in the relationship between major depression and cardiovascular disorders - The German Health Interview and Examination Survey. (20073117)
Baune B.T.... Berger K.
|30|Research letter: Psychotherapy increases brain serotonin 5-HT1A receptors in patients with major depressive disorder. (19903365)
Karlsson H.... Hietala J.
|31|Disorder specificity despite comorbidity: resting EEG alpha asymmetry in major depressive disorder and post-traumatic stress disorder. (20708650)
Kemp A.H.... Bryant R.A.
|32|Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression. (20080186)
Monteleone P.... Maj M.
|33|A cis-phase interaction study of genetic variants within the MAOA gene in major depressive disorder. (20691428)
Zhang J.... Xu Q.
|34|The combined effects of the BDNF and GSK3B genes modulate the relationship between negative life events and major depressive disorder. (20682308)
Yang C.... Zhang K.
|35|Association of the adrenergic alpha 2a receptor--1291C/G polymorphism with weight change and treatment response to mirtazapine in patients with major depressive disorder. (19401164)
Lee H.Y.... Lee M.S.
|36|Effect of the 5-HTTLPR polymorphism in the serotonin transporter gene on major depressive disorder and related comorbid disorders. (19125107)
Verhagen M.... Franke B.
|37|Monoamine oxidase a and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder. (19593178)
Leuchter A.F.... Alpert J.E.
|38|Characterization of QKI gene expression, genetics, and epigenetics in suicide victims with major depressive disorder. (19545858)
Klempan T.A.... Turecki G.
|39|Association study between the serotonin 1A receptor (HTR1A) gene and neuroticism, major depression, and anxiety disorders. (18163385)
Hettema J.M.... Chen X.
|40|Comparing postpartum depression and major depressive disorder: issues in assessment. (17654110)
Jolley S.N.... Betrus P.
|41|Neurocognitive differential diagnosis of dementing diseases: Alzheimer's Dementia, Vascular Dementia, Frontotemporal Dementia, and Major Depressive Disorder. (17000529)
Braaten A.J.... Burns W.J.
|42|Association between COMT (Val158Met) functional polymorphism and early onset in patients with major depressive disorder in a European multicenter genetic association study. (15583702)
Massat I.... Mendlewicz J.
|43|Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia. (14744462)
LA^pez-Figueroa A.L.... Watson S.J.
|44|Association of a MAOA gene variant with generalized anxiety disorder, but not with panic disorder or major depression. (12555227)
Tadic A.... Dahmen N.
|45|Association study of the interleukin-1 beta (C-511T) genetic polymorphism with major depressive disorder, associated symptomatology, and antidepressant response. (12700687)
Yu Y.W.... Tsai S.J.
|46|Tumor necrosis factor-beta gene polymorphism may not be associated with major depressive disorder in the Korean population. (12519452)
Jun T.Y.... Han H.
|47|Serotonin transporter polymorphism and response to SSRIs in major depression and relevance to anxiety disorders and substance abuse. (11256582)
Weizman A.... Weizman R.
|48|Intergenerational CAG repeat expansion at ERDA1 in a family with childhood-onset depression, schizoaffective disorder, and recurrent major depression. (10050972)
Vincent J.B.... Kennedy J.L.
|49|Fluoxetine, but not tricyclic antidepressants, potentiates the 5-hydroxytryptophan-mediated increase in plasma cortisol and prolactin secretion in subjects with major depression or with obsessive compulsive disorder. (9194044)
Meltzer H.... Maes M.
|50|Major depression versus organic mood disorder: a questionable distinction. (2404962)